Inventor · disambiguated record
Patricia K. Donahoe
Also filed as: DONAHOE PATRICIA · DONAHOE PATRICIA K
28 granted patents·8 pending applications·696 citations·filing 1981–2024
97Inventor score
Files withGEN HOSPITAL CORP19MASSACHUSETTS GEN HOSPITAL12BIOGEN INC2DONAHOE PATRICIA K2TEIXEIRA JOSE1
Top patents by PatentIndex Score
36 records- 0193US6692738B2Delivery of therapeutic biologicals from implantable tissue matricesGEN HOSPITAL CORP·Filed 2001·Granted Feb 17, 2004·202 cites·8 claims
- 0290US5538892ANucleic acids encoding a TGF-β type 1 receptorGEN HOSPITAL CORP·Filed 1993·Granted Jul 23, 1996·83 cites·21 claims
- 0386US11135269B2Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservationMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted Oct 5, 2021·3 cites·12 claims
- 0482US6673352B1Use of Mullerian inhibiting substance for treating excess androgen statesGEN HOSPITAL CORP·Filed 2000·Granted Jan 6, 2004·18 cites·15 claims
- 0582US2024277812A1Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservationMASSACHUSETTS GEN HOSPITAL·Filed 2024·Application pending·0 cites
- 0681US5547854ADNA encoding a receptor for Mullerian inhibitory substance, misr1, and corresponding vectors, cells, probes, and recombinant methodsGEN HOSPITAL CORP·Filed 1994·Granted Aug 20, 1996·42 cites·27 claims
- 0780US5047336ADNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptidesBIOGEN INC·Filed 1985·Granted Sep 10, 1991·26 cites·15 claims
- 0878US12486309B2Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservationMASSACHUSETTS GEN HOSPITAL·Filed 2022·Granted Dec 2, 2025·0 cites·28 claims
- 0977US5661126AUse of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expressionGEN HOSPITAL CORP·Filed 1994·Granted Aug 26, 1997·49 cites·23 claims
- 1074US4404188APurified Mullerian Inhibiting Substance and method of purificationMASSACHUSETTS GEN HOSPITAL·Filed 1981·Granted Sep 13, 1983·36 cites·6 claims
- 1173US5198420AUse of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndromeGEN HOSPITAL CORP·Filed 1992·Granted Mar 30, 1993·53 cites·9 claims
- 1272US5010055AUse of EGF to reverse the contraceptive activity of MISGEN HOSPITAL CORP·Filed 1987·Granted Apr 23, 1991·23 cites·4 claims
- 1370US9791449B2Ovarian cancer stem cells and methods of isolation and uses thereofDONAHOE PATRICIA K·Filed 2012·Granted Oct 17, 2017·2 cites·6 claims
- 1470US4487833AMethod of preparing hybridomas and of purifying immunogenic materialsGEN HOSPITAL CORP·Filed 1982·Granted Dec 11, 1984·27 cites·21 claims
- 1570US2010233689A1Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen statesGEN HOSPITAL CORP·Filed 2008·Application pending·0 cites
- 1669US11998590B2Use of Mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservationMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Jun 4, 2024·0 cites·31 claims
- 1766US4792601AMonoclonal antibody to mullerian inhibiting substanceGEN HOSPITAL CORP·Filed 1984·Granted Dec 20, 1988·20 cites·3 claims
- 1865US4510131APurified Mullerian Inhibiting Substance and method of useGEN HOSPITAL CORP·Filed 1983·Granted Apr 9, 1985·20 cites·3 claims
- 1963US4753794AUse of mullerian inhibiting substance as a contraceptive agentGEN HOSPITAL CORP·Filed 1986·Granted Jun 28, 1988·25 cites·6 claims
- 2061US12497437B2Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseasesMASSACHUSETTS GEN HOSPITAL·Filed 2021·Granted Dec 16, 2025·0 cites·19 claims
- 2161US11518793B2Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservationMASSACHUSETTS GEN HOSPITAL·Filed 2017·Granted Dec 6, 2022·0 cites·9 claims
- 2260US10258668B2Viral vectors for expressing a modified mullerian inhibiting substance (MIS) proteinMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted Apr 16, 2019·0 cites·10 claims
- 2359US2024218038A1Compositions and methods for preventing or delaying puberty in prepubescent non-human animals and humansMASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 2457US2016199352A1Pyrazoloanthrone and derivatives thereof for treatment of cancers expressing missriiGEN HOSPITAL CORP·Filed 2016·Application pending·0 cites
- 2556US9260759B2Pyrazoloanthrone and derivatives thereof for the treatment of cancers expressing MISRIITEIXEIRA JOSE·Filed 2011·Granted Feb 16, 2016·0 cites·7 claims
- 2655US9289492B2Collecting ovarian cancer stem cells from ovarian cancer cellsDONAHOE PATRICIA K·Filed 2008·Granted Mar 22, 2016·2 cites·11 claims
- 2755US7078032B2Delivery of therapeutic biologicals from implantable tissue matricesGEN HOSPITAL CORP·Filed 2003·Granted Jul 18, 2006·17 cites·7 claims
- 2855US2016250190A1N-methyl pyrazoloanthrone for treatment of cancerMASSACHUSETTS GEN HOSPITAL·Filed 2014·Application pending·0 cites
- 2955US2004062750A1Use of mullerian inhibiting substance for treating excess androgen statesGEN HOSPITAL CORP·Filed 2003·Application pending·0 cites
- 3055US2019351026A1Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseasesMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 3154US11084860B2Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseasesMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted Aug 10, 2021·0 cites·14 claims
- 3252US2004151693A1Use of mullerian inhibiting substance and interferon for treating tumorsGEN HOSPITAL CORP·Filed 2003·Application pending·0 cites
- 3351US5310880APurification of Mullerian inhibiting substanceGEN HOSPITAL CORP·Filed 1991·Granted May 10, 1994·12 cites·9 claims
- 3451US5011687APurified Mullerian inhibiting substance and process for treating human ovarian cancer cellsGEN HOSPITAL CORP·Filed 1985·Granted Apr 30, 1991·15 cites·2 claims
- 3548US5912224AMethods and compositions for enhancing cellular response to TGF-β ligandsGEN HOSPITAL CORP·Filed 1997·Granted Jun 15, 1999·14 cites·31 claims
- 3646US5427780AComposition comprising Mullerian inhibiting substance-like polypeptidesBIOGEN INC·Filed 1992·Granted Jun 27, 1995·7 cites·1 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →